SCHEMBL23698707

SCHEMBL23698707

CN(C)C(=O)Oc1ccc([N+](=O)[O-])c2cccnc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.65
GAA P10253 3/20 0.65
JMJD7 P0C870 1/20 0.58
MAPT P10636 11/20 0.56
KMT2A Q03164 6/20 0.56
ALDH1A1 P00352 5/20 0.56
MEN1 O00255 5/20 0.56
LMNA P02545 4/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
ALOX12 P18054 2/20 0.56
CTSB P07858 2/20 0.56
HTT P42858 2/20 0.56
NPC1 O15118 1/20 0.56
BRD4 O60885 1/20 0.56
HSP90AA1 P07900 1/20 0.56
CHRM1 P11229 1/20 0.56
DRD2 P14416 1/20 0.56
ADRA2B P18089 1/20 0.56
ADRA2C P18825 1/20 0.56
CHRM3 P20309 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19182403 0.90 KDM4E (0.58) KDM4EGAAJMJD7MAPTKMT2A
SCHEMBL29066537 0.88 JMJD7 (0.56) KDM4EGAAJMJD7MAPTKMT2A
SCHEMBL29066538 0.87 KDM4E (0.67) KDM4EGAAJMJD7MAPTKMT2A
SCHEMBL30421287 0.86 JMJD7 (0.53) KDM4EGAAJMJD7MAPTKMT2A
SCHEMBL21816873 0.86 JMJD7 (0.53) KDM4EGAAJMJD7MAPTKMT2A
SCHEMBL23715733 0.86 MAPT (0.51) KDM4EGAAJMJD7MAPTKMT2A
SCHEMBL23698662 0.85 JMJD7 (0.52) KDM4EGAAJMJD7MAPTKMT2A
SCHEMBL29066519 0.85 KDM4E (0.56) KDM4EGAAJMJD7MAPTKMT2A
SCHEMBL6974167 0.84 JMJD7 (0.63) KDM4EGAAJMJD7MAPTKMT2A
SCHEMBL29066525 0.83 JMJD7 (0.49) KDM4EGAAJMJD7MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12152048-B2 Nitroxoline prodrug and use thereof JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2024-11-26 US disclosed
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2021-11-25 US disclosed
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2021-11-25 US disclosed
EP-3858814-A1 NITROXOLINE PRODRUG AND USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2021-08-04 EP disclosed
EP-3858814-A1 NITROXOLINE PRODRUG AND USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2021-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12152048-B2 Nitroxoline prodrug and use thereof NOS1, NOS2, NNT KDM4E 2742/4885GAA 2690/4885JMJD7 2021/4885
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF NOS1, NOS2, NNT KDM4E 2742/4885GAA 2690/4885JMJD7 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.